Anticoagulant versus antiplatelet treatment for secondary stroke prevention in patients with active cancer

Approximately 5-10% of patients with acute ischemic stroke (AIS) have known active cancer. These patients are at high risk for both recurrent AIS and major bleeding. The optimal antithrombotic strategy for cancer-related stroke is uncertain. This study compared clinical outcomes among patients with...

Full description

Bibliographic Details

Published in:	Frontiers in neurology Vol. 16; p. 1530775
Main Authors:	Kielkopf, Moritz C., Göcmen, Jayan, Venzin, Selina B., Steinauer, Fabienne, Branca, Mattia, Boronylo, Anna, Göldlin, Martina B., Kaesmacher, Johannes, Mujanovic, Adnan, Costamagna, Gianluca, Meinel, Thomas R., Seiffge, David J., Bücke, Philipp, Heldner, Mirjam R., Liberman, Ava L., Kamel, Hooman, Fischer, Urs, Arnold, Marcel, Pabst, Thomas, Berger, Martin D., Jung, Simon, Scutelnic, Adrian, Navi, Babak B., Beyeler, Morin
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 2025
Subjects:	acute ischemic stroke antithrombotic drugs cancer embolic stroke of unknown source (ESUS) secondary prevention cancer secondary prevention antithrombotic drugs embolic stroke of unknown source (ESUS) acute ischemic stroke
ISSN:	1664-2295, 1664-2295
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!